Di Fan | Molecular Imaging in Drug Development | Best Researcher Award

Ms. Di Fan | Molecular Imaging in Drug Development | Best Researcher Award

Capital Medical University | China

AUTHOR PROFILE

Scopus

đź“Ś DI FAN, PhD

Associate Researcher
Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University

🎓 EDUCATION AND EARLY ACADEMIC PURSUITS

Di Fan pursued his Bachelor’s degree at Wuhan University (2006-2010), where he built a strong foundation in biomedical sciences. His passion for advanced medical research led him to Peking University (2010-2015), where he obtained his PhD. During his doctoral studies, he focused on radiopharmaceuticals and molecular imaging, setting the stage for a career dedicated to cutting-edge advancements in nuclear medicine.

🏥 PROFESSIONAL ENDEAVORS

Currently serving as an Associate Researcher at the Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Di Fan plays a pivotal role in advancing molecular imaging and targeted cancer therapies. His work bridges the gap between innovative radiopharmaceuticals and their clinical applications, contributing to the early detection and treatment of cancer.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Fan’s research is primarily focused on:

  • Radiopharmaceutical Development – Designing novel radioactive tracers for precise cancer imaging and treatment.
  • Molecular Imaging – Utilizing advanced PET and SPECT imaging techniques to enhance tumor detection and therapeutic monitoring.
  • Targeted Cancer Therapy – Developing radiolabeled compounds to selectively attack cancer cells, minimizing damage to healthy tissues.

His work contributes significantly to improving personalized cancer treatment, ensuring higher accuracy in diagnosis and therapy.

🌍 IMPACT AND INFLUENCE

Dr. Fan’s contributions have been recognized through numerous scientific publications, collaborations with leading medical institutions, and participation in national and international research projects. His expertise in nuclear medicine and molecular imaging has influenced both clinical practices and medical innovations in China and beyond.

đź“š ACADEMIC CITES AND RECOGNITION

  • Published extensively in high-impact SCI-indexed journals related to radiopharmaceuticals and cancer imaging.
  • H-index and citations reflect his significant contribution to the field of nuclear medicine.
  • Regularly invited to present at global medical and radiology conferences, sharing insights on novel imaging techniques.

🚀 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Fan aims to:
âś… Develop next-generation radiopharmaceuticals for better cancer detection and treatment.
âś… Strengthen collaborations between academic and clinical institutions to enhance nuclear medicine applications.
âś… Advance precision oncology, integrating AI-driven analysis for personalized cancer therapies.

His research will continue shaping the future of molecular imaging and targeted therapies, ensuring breakthroughs in early cancer diagnosis and patient-centered treatments.

🧬CONCLUSION

Dr. Di Fan stands at the forefront of nuclear medicine research, making significant strides in radiopharmaceuticals, molecular imaging, and targeted cancer therapy. His dedication to scientific innovation and clinical application has not only enhanced cancer diagnostics and treatment but also paved the way for more effective and personalized medical approaches.

 

📊🔬NOTABLE PUBLICATION:
    1. Title: Utilisation of the Innovative [18F]-Labelled Radiotracer [18F]-BIBD-071 Within HR+ Breast Cancer Xenograft Mouse Models
      Authors: D., Fan, Di , X., Wang, Xin , X., Ling, Xueyuan , … Z., Wu, Zehui , L., Ai, Lin
      Journal: Pharmaceuticals
      Year: 2025

Prof Dr. Rommel MarioRodriguez Burbano – Oncology and Precision Medicine – Best Researcher Award

Prof Dr. Rommel MarioRodriguez Burbano - Oncology and Precision Medicine - Best Researcher Award

Ophir Loyola Hospital - Brazil

AUTHOR PROFILE

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Rommel Mario Rodríguez Burbano began his academic journey by earning a degree in Biomedicine from the Federal University of Pará in 1989. He then pursued further education, completing his Master's (1993) and Ph.D. (1998) in Biological Sciences (Genetics) from the Faculty of Medicine of Ribeirão Preto, University of São Paulo.

PROFESSIONAL ENDEAVORS

After completing his formal education, Rommel embarked on a diverse and impactful professional career. He conducted post-doctoral research in Morphology at the Discipline of Genetics, Escola Paulista de Medicina, Federal University of São Paulo in 2005. Currently, he holds the prestigious position of Full Professor at the Federal University of Pará.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Rommel Mario RodrĂ­guez Burbano's contributions to academia are significant and multifaceted. His research primarily focuses on Human Genetics, Cell Biology, and Oncology. Throughout his career, he has demonstrated a keen interest in understanding molecular mechanisms underlying diseases, particularly cancer.

IMPACT AND INFLUENCE

Rommel's work has had a profound impact on the scientific community. His extensive publication record, comprising 296 scientific articles in specialized journals, one book, and seven book chapters, reflects his dedication to advancing knowledge in his field.

ACADEMIC CITATIONS

Rommel's research output has garnered considerable attention, as evidenced by his numerous academic citations. His work is widely recognized and cited by peers, contributing significantly to the advancement of scientific knowledge.

LEGACY AND FUTURE CONTRIBUTIONS

As a mentor and supervisor, Rommel has played a pivotal role in shaping the next generation of scientists. He has supervised a total of 44 master's theses, 41 doctoral theses, and mentored five postdoctoral fellows. His legacy extends beyond his own research contributions, influencing the work of numerous scholars who have benefited from his guidance and expertise.

HIGHLIGHTS

Rommel currently serves as the Coordinator of the Molecular Biology Laboratory at Hospital Ophir Loyola in Belém, Pará, indicating his leadership in translational research.He holds the Process and Molecular Biomarker patent, demonstrating his innovative approach to addressing scientific challenges.Rommel's involvement in editorial boards of 12 scientific journals and his role as a reviewer for numerous scientific publications underscore his commitment to peer-reviewed research and quality scholarship.

NOTABLE PUBLICATIONS

Homocystein, Vitamin B12 and Folic Acid as Screening Biomarkers in Early Diagnosis and Gastric Cancer Monitoring.  2024

Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials. 2024

Molecular Profile of Variants Potentially Associated with Severe Forms of COVID-19 in Amazonian Indigenous Populations. 2024 (1)

Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials. 2024

PARP1 Characterization as a Potential Biomarker for BCR::ABL1 p190+ Acute Lymphoblastic Leukemia. 2023